**Supplementary Table 1.** Baseline Characteristics of the Patients Newly Receiving Alogliptin

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  | Unknown |
| 　 | age <65 | age 65-74 | age ≥75 | p | 　 | age <65 | age 65-74 | age ≥75 |
| Male/Female | 54 (65.1%)/28 (33.7%) | 30 (50.8%)/29 (49.2%) | 35 (48.6%)/35 (48.6%) | 0.151  | 　 | 1 (1.2%) | 0 (0%) | 2 (2.8%) |
| Age | 55.5 ± 7.2 | 70.1 ± 2.9 | 79.6 ± 3.9 | <0.001 | † | 0 (0%) | 0 (0%) | 0 (0%) |
| Disease duration | 7.2 ± 5.6 | 10.5 ± 8 | 12.1 ± 8.3 | 0.005  | † | 30 (36.1%) | 20 (33.9%) | 32 (44.4%) |
| Diabetic retinopathy | 4 (4.8%) | 7 (11.9%) | 4 (5.6%) | 0.224  | 　 | 14 (16.9%) | 8 (13.6%) | 18 (25%) |
| Diabetic neuropathy | 2 (2.4%) | 5 (8.5%) | 8 (11.1%) | 0.222  | 　 | 14 (16.9%) | 12 (20.3%) | 15 (20.8%) |
| Diabetic nephropathy | 8 (9.6%) | 7 (11.9%) | 7 (9.7%) | 0.853  | 　 | 12 (14.5%) | 10 (16.9%) | 15 (20.8%) |
| Cerebrovascular disorders | 5 (6%) | 6 (10.2%) | 7 (9.7%) | 0.511  | 　 | 15 (18.1%) | 8 (13.6%) | 17 (23.6%) |
| Myocardial infarction | 2 (2.4%) | 5 (8.5%) | 5 (6.9%) | 0.291  | 　 | 15 (18.1%) | 8 (13.6%) | 17 (23.6%) |
| Angina pectoris | 4 (4.8%) | 10 (16.9%) | 9 (12.5%) | 0.077  | 　 | 15 (18.1%) | 7 (11.9%) | 17 (23.6%) |
| Arteriosclerosis obliterans | 2 (2.4%) | 2 (3.4%) | 2 (2.8%) | 0.530  | 　 | 18 (21.7%) | 12 (20.3%) | 23 (31.9%) |
| Hypertension | 42 (50.6%) | 37 (62.7%) | 46 (63.9%) | 0.343  | 　 | 11 (13.3%) | 6 (10.2%) | 10 (13.9%) |
| Dyslipidemia | 46 (55.4%) | 36 (61%) | 31 (43.1%) | 0.282  | 　 | 11 (13.3%) | 6 (10.2%) | 14 (19.4%) |
| Hepatic steatosis | 19 (22.9%) | 9 (15.3%) | 5 (6.9%) | 0.070  | 　 | 18 (21.7%) | 13 (22%) | 23 (31.9%) |
| Others | 16 (19.3%) | 17 (28.8%) | 20 (27.8%) | 0.465  | 　 | 23 (27.7%) | 12 (20.3%) | 21 (29.2%) |
| Smoking history | 17 (20.5%) | 14 (23.7%) | 9 (12.5%) | 0.355  | 　 | 32 (38.6%) | 20 (33.9%) | 35 (48.6%) |
| Drinking history | 31 (37.3%) | 17 (28.8%) | 12 (16.7%) | 0.038  | \* | 26 (31.3%) | 19 (32.2%) | 35 (48.6%) |
| Family history | 22 (26.5%) | 9 (15.3%) | 5 (6.9%) | <0.001 | \* | 37 (44.6%) | 22 (37.3%) | 49 (68.1%) |

\*p<0.05 Chi-squared test (excluding “Unknown” cases),†p<0.05 ANOVA